CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis

Cancer Research

Volumn 71, Issue 8, 2011, Pages 2892-2900

  Stagg, John ^a,b   Divisekera, Upulie ^a   Duret, Helene ^a   Sparwasser, Tim ^c   Teng, Michele W L ^a,d   Darcy, Phillip K ^a,d   Smyth, Mark J ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD73; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GENE TARGETING; HEMATOPOIETIC CELL; IN VIVO STUDY; LUNG METASTASIS; LYMPHOMA; MELANOMA; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T CELL DEPLETION; TUMOR ESCAPE; TUMOR IMMUNITY;

5'-NUCLEOTIDASE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL;

EID: 79954576658     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4246     Document Type: Article

References (35)

1. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, Van Der Meer JH, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009;113:2324-35.
2. Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A 2008;105:8067-72. (Pubitemid 351904709)
3. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;29:5346-58.
4. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: Tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008;14:5947-52.
5. Sitkovsky MV. T regulatory cells: Hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol 2009; 30:102-8.
6. Ohta A, Sitkovsky M. Methylxanthines, inflammation, and cancer: Fundamental mechanisms. Handb Exp Pharmacol 2011:469-81.
7. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001;414:916-20. (Pubitemid 34024743)
8. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006;103:13132-7. (Pubitemid 44338928)
9. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 2003;15:813-27. (Pubitemid 36776656)
10. Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 2009;183:5487-93.
11. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65. (Pubitemid 46919862)
12. Zhang H, Conrad DM, Butler JJ, Zhao C, Blay J, Hoskin DW. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: Role of cyclic adenosine 3',5'-monophosphate and phosphatases. J Immunol 2004;173:932-44. (Pubitemid 38924266)
13. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, et al. A2A receptor signaling promotes peripheral tolerance by inducing Tcell anergy and the generation of adaptive regulatory T cells. Blood 2008;111:251-9.
14. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 2010;107:1547-52.
15. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998;161:95-109.
16. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2006;2:351-60.
17. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002;110:993-1002.
18. Niemela J, Henttinen T, Yegutkin GG, Airas L, Kujari AM, Rajala P, et al. IFN-alpha induced adenosine production on the endothelium: A mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation. J Immunol 2004;172:1646-53. (Pubitemid 38116812)
19. Bavaresco L, Bernardi A, Braganhol E, Cappellari AR, Rockenbach L, Farias PF, et al. The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 2008;319:61-8.
20. Spychala J, Kitajewski J. Wnt and beta-catenin signaling target the expression of ecto-5'-nucleotidase and increase extracellular adenosine generation. Exp Cell Res 2004;296:99-108. (Pubitemid 38624632)
21. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res 2010;70:2245-55.
22. Takedachi M, Qu D, Ebisuno Y, Oohara H, Joachims ML, McGee ST, et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol 2008;180:6288-96.
23. Ring S, Enk AH, Mahnke K. ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions. J Immunol 2010;184:3408-16.
24. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gammastimulated marrow stromal cells: A new type of nonhematopoietic antigen-presenting cell. Blood 2006;107:2570-7. (Pubitemid 43348704)
25. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008;205:2965-73.
26. Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 2007;179:2851-9.
27. Stagg J, Wu JH, Bouganim N, Galipeau J. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 2004;64:8795-9. (Pubitemid 39665478)
28. + T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
29. +regulatory T cells. J Biol Chem 2010;285:7176-86.
30. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010;70:7800-9.
31. + regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010;70:7788-99.
32. Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O'Gorman WE, et al. Cutting edge: Mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 2010;185:6426-30.
33. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204:1303-10. (Pubitemid 46919868)
34. + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010;139:1030-40.
35. Mills JH, Thompson LF, Mueller C, Waickman AT, Jalkanen S, Niemela J, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008;105:9325-30.